Some Hong Kong-listed innovative drug concept stocks performed notably well today. Wuxi Apptec surged over 3%, while Wuxi Bio and JOINN Laboratories rose nearly 2%. Recent policy support for the innovative drug sector has significantly increased: the National Medical Products Administration's "Spring Rain Initiative" explicitly supports clinical innovation in medical devices, the government work report for the first time listed biomedicine as an "emerging pillar industry," and the expansion of the national insurance drug list (adding 50 Class 1 innovative drugs) among others. Policy tailwinds combined with business development (BD) partnerships are expected to accelerate the value reassessment of innovative drug companies. Would you consider investing in the innovative drug sector?